- Home
- BLCO
as 08-05-2025 12:32pm EST
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.
| Founded: | 1853 | Country: | Canada |
| Employees: | N/A | City: | VAUGHAN |
| Market Cap: | 4.9B | IPO Year: | 2022 |
| Target Price: | $15.80 | AVG Volume (30 days): | 903.7K |
| Analyst Decision: | Hold | Number of Analysts: | 11 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.78 | EPS Growth: | N/A |
| 52 Week Low/High: | $10.45 - $21.69 | Next Earning Date: | 07-30-2025 |
| Revenue: | $4,891,000,000 | Revenue Growth: | 8.81% |
| Revenue Growth (this year): | 7.1% | Revenue Growth (next year): | 5.50% |
Stock Insider Trading Activity of Bausch + Lomb Corporation (BLCO)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| SAUNDERS BRENT L | BLCO | CEO and Chairman of the Board | May 22 '25 | Buy | $11.28 | 22,000 | $248,072.00 | 719,156 |
Latest Bausch + Lomb Corporation News
BLCO Breaking Stock News: Dive into BLCO Ticker-Specific Updates for Smart Investing
MT Newswires
a month ago
Bausch + Lomb Closes Floating Rate Note Offering, Refinances Credit Facilities
MT Newswires
a month ago
Bausch + Lomb Closes Senior Secured Notes Offering, Refinancing And Upsizes US$2.32 Billion Term Loan Facility
Business Wire
a month ago
Bausch + Lomb Announces Closing of Upsized €675 Million Senior Secured Notes Offering and Partial Credit Agreement Refinancing, Including Upsized $2.325 Billion Term Loan Facility
StockStory
a month ago
The Top 5 Analyst Questions From Bausch + Lomb’s Q1 Earnings Call
Insider Monkey
a month ago
Barclays Cut Bausch & Lomb Target to $16, Keeping Rating Neutral in Early June
MT Newswires
2 months ago
Bausch + Lomb Prices Upsizes and Prices a 675-Million Euro Senior Secured Notes Offering
Business Wire
2 months ago
Bausch + Lomb Announces Pricing of Upsized Senior Secured Notes Offering
Business Wire
2 months ago
Bausch + Lomb Announces Launch of Senior Secured Notes Offering and Refinancing of Credit Agreement
Compare BLCO vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "BLCO Bausch + Lomb Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.